Use of fumaric acid esters in psoriasis

Area of Science:

• Dermatology
• Pharmacology

Background:

• Fumaric acid esters (FAE) are derived from fumaric acid.
• Oral preparations containing dimethylfumarate (DMF) and monoethylfumarate (MEF) salts were developed in the 1980s.
• Fumaderm, an FAE preparation, has been a standard systemic psoriasis treatment in Germany since 1994.

Purpose of the Study:

• To review the pharmacokinetics, uses, contraindications, dosages, and side effects of FAE treatment for psoriasis.

Main Methods:

• Review of existing literature on FAEs for psoriasis treatment.

Main Results:

• FAE therapy is effective for psoriasis, with 50-70% of patients achieving PASI 75 improvement within four months.
• Treatment is associated with no long-term toxicity, immunosuppressive effects, or increased risk of infection or malignancy.
• Common side effects include gastrointestinal issues and skin flushing.

Conclusions:

• Fumaric acid esters represent an effective systemic therapy for psoriasis.
• The exact mechanisms of action require further elucidation.
• Patient tolerance can be limited by side effects, necessitating careful management.